Health Care [ 9/12 ] | Biotechnology [ 65/74 ]
NASDAQ | Common Stock
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology.
Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
The company's vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate.
Its vaccine technologies focus on the discovery of additional retired proteins that may be associated with other forms of cancer.
The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018.
Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 21, 25 | -0.10 Increased by 0.00% | -0.10 |
| Jan 1, 25 | -0.09 Increased by 0.00% | -0.11 Increased by +18.18% |
| Sep 6, 24 | -0.10 Decreased by -25.00% | -0.11 Increased by +9.09% |
| Jun 4, 24 | -0.10 Decreased by -42.86% | -0.11 Increased by +9.09% |
| Mar 12, 24 | -0.10 Decreased by -25.00% | -0.09 Decreased by -11.11% |
| Jan 16, 24 | -0.09 Increased by +25.00% | -0.09 |
| Sep 6, 23 | -0.08 Increased by +11.11% | -0.09 Increased by +11.11% |
| Jun 14, 23 | -0.07 Increased by +41.67% | -0.11 Increased by +36.36% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jan 31, 25 | 0.00 Decreased by N/A% | -3.18 M Increased by +2.18% | Decreased by N/A% Decreased by N/A% |
| Oct 31, 24 | 0.00 Decreased by -100.00% | -2.88 M Decreased by -7.17% | Decreased by N/A% Decreased by N/A% |
| Jul 31, 24 | 0.00 Decreased by N/A% | -3.28 M Decreased by -30.51% | Decreased by N/A% Decreased by N/A% |
| Apr 30, 24 | 0.00 Decreased by -100.00% | -3.14 M Decreased by -54.25% | Decreased by N/A% Decreased by N/A% |
| Jan 31, 24 | 0.00 Decreased by N/A% | -3.25 M Decreased by -53.54% | Decreased by N/A% Decreased by N/A% |
| Oct 31, 23 | 156.00 K Decreased by -99.99% | -2.69 M Increased by +20.79% | Decreased by -1.72 K% Decreased by -1.25 M% |
| Jul 31, 23 | 0.00 Decreased by N/A% | -2.51 M Increased by +7.07% | Decreased by N/A% Decreased by N/A% |
| Apr 30, 23 | 210.00 K Increased by +N/A% | -2.04 M Increased by +42.55% | Decreased by -969.05% Decreased by N/A% |